RCEL(AVITA Medical, Inc.) 的财务报表:医疗保健,医疗器械。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-06-30 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $29.23M | $34.42M | $50.14M | $64.25M | $71.61M |
| 毛利润 | $23.28M | $28.38M | $42.36M | $55.16M | $58.82M |
| 营业利润 | −$26.54M | −$27.50M | −$42.66M | −$56.59M | −$42.53M |
| 净利润 | −$26.58M | −$26.66M | −$35.38M | −$61.84M | −$48.59M |
| 经营现金流 | −$25.90M | −$19.09M | −$38.01M | −$48.94M | −$31.20M |
| 自由现金流 | −$26.80M | −$19.54M | −$39.39M | −$58.11M | −$32.20M |
| 摊薄每股收益 | — | — | $-1.40 | $-2.39 | $-1.74 |